Last Friday, the FDA approved the SGLT2 inhibitor dapaglifozin. This is the second drug in the SGLT2-I class and so now the battle of superiority, dapagliflozin versus canagliflozin, begins. There will also be extra pressure from the DPP4-I companies to downplay the value of this drug class. This week, in Part 7 of our Homerun Slides, Dr. Stanley Schwartz discusses this new class in detail. His information will educate you enough to flush out the marketing hoopla.
Our Clinical Case examines the differences between confusion due to old age and the disorientation that could be due to a diabetic medical emergency, and our Disaster Averted looks at the value for your patients of having an updated personal medical history with them at all times. Our Mastery In Minutes video with Dr. Peter Nilsson focuses on the relationship between hypertension and diabetes.